艾德生物成立于2008年2月21日，于2017年8月2日在深圳证券交易所上市，注册及办公地址均为福建省厦 门市。它是国内肿瘤精准医疗分子诊断领域的领先企业，拥有全流程技术平台和丰富的产品管线。 艾德生物主营业务为肿瘤精准医疗分子诊断产品的研发、生产及销售，并提供相关的检测服务，所属申万 行业为医药生物 - 医疗器械 - 体外诊断，涉及基因测序、体外诊断、精准医疗等概念板块。 经营业绩：营收行业第12，净利润行业第5 2025年三季度，艾德生物实现营业收入8.66亿元，在行业39家公司中排名第12。行业第一名新产业营收 34.28亿元，第二名安图生物营收31.27亿元，行业平均数为7.08亿元，中位数为3.3亿元。主营业务构成 中，检测试剂4.83亿元占比83.43%，药物临床研究服务5698.83万元占比9.84%，检测服务3250.49万元占比 5.61%，其他（补充）651.67万元占比1.12%。当期净利润为2.63亿元，行业排名第5，行业第一名九安医疗 净利润15.88亿元，第二名新产业净利润12.05亿元，行业平均数为1.1亿元，中位数为2618.92万元。 资产负债率低于同业平均，毛利率高于同业平 ...

Core Viewpoint - Lidman has experienced a significant stock price increase of 51.84% year-to-date, despite a recent decline in the last five and twenty trading days [2]. Company Overview - Beijing Lidman Biochemical Co., Ltd. was established on November 5, 1997, and listed on February 16, 2012. The company specializes in in vitro diagnostic reagents (biochemical, immunological, molecular), diagnostic instruments, and biochemical raw materials [2]. - The revenue composition of Lidman includes: in vitro diagnostic reagents 67.84%, diagnostic instruments 14.17%, other (property leasing/management, etc.) 13.21%, and biochemical raw materials 4.78% [2]. Stock Performance - As of October 31, Lidman's stock price was 7.44 CNY per share, with a market capitalization of 4.047 billion CNY. The stock saw a trading volume of 47.6122 million CNY and a turnover rate of 1.19% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the most recent appearance on August 8 [2]. Financial Performance - For the period from January to September 2025, Lidman reported a revenue of 252 million CNY, a year-on-year decrease of 10.49%. The net profit attributable to the parent company was -7.1348 million CNY, a decrease of 765.83% year-on-year [2]. - The company has distributed a total of 143 million CNY in dividends since its A-share listing, with 5.4401 million CNY distributed in the last three years [3]. Shareholder Information - As of October 20, 2025, Lidman had 33,600 shareholders, an increase of 1.96% from the previous period. The average circulating shares per person decreased by 1.92% to 16,170 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 2.0113 million shares, while Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund (004685) and Huaxia CSI 500 Index Enhanced A (007994) have exited the top ten [3].

Core Insights - The recombinant protein industry in China, despite its late start, has rapidly developed due to continuous support from national industrial policies, leading to significant breakthroughs in technology, production processes, and quality control [1][15] - The market for recombinant proteins is expected to grow steadily, driven by increased investment in innovative drug research, rising demand for precision medicine, and the expansion of downstream application scenarios [1][15] Industry Overview - Recombinant proteins are proteins obtained through genetic engineering and cell engineering, essential for the development and production of biopharmaceuticals, cell immunotherapy, and diagnostic reagents [4] - The industry has experienced three stages: the initial stage (1970-1990), rapid development (1990-2000), and transformation and upgrading (2000-present) [8][9] Market Growth - The market size of China's recombinant protein industry is projected to grow from 5.1 billion yuan in 2015 to 27 billion yuan in 2024, with a compound annual growth rate (CAGR) of 20.34% [1][15] - The global recombinant protein market is expected to increase from $7 billion in 2015 to $18.5 billion in 2024, with a CAGR of 11.4% [13][14] Policy Support - The Chinese government has implemented various policies to encourage technological innovation and market expansion in the biopharmaceutical sector, including funding support for research and expedited drug approval processes [9][10] Industry Chain - The upstream of the recombinant protein industry includes raw materials and equipment, while the midstream consists of recombinant protein products, and the downstream includes customers such as research institutions and pharmaceutical companies [10] Competitive Landscape - The recombinant protein market is characterized by a diverse and dynamic competitive landscape, with major multinational pharmaceutical companies like Pfizer, Roche, and Novartis leading the market, while numerous small and medium-sized enterprises focus on innovative technologies [16][17] Development Trends - The industry is moving towards high-end products, focusing on complex structures and high-value proteins, with an emphasis on product activity, purity, and consistency [18] - Intelligent technologies, including AI and machine learning, are expected to enhance research and production processes, improving efficiency and product quality [19][20] - Chinese recombinant protein companies are increasingly participating in global competition, aiming to meet international standards and establish a strong global presence [21]

对于像特雷 · 艾德克这样的科学家来说，这一前景既令人振奋，又显得不够全面。艾德克在美国卫生与 公众服务部（ U.S. Department of Health and Human Services ）下属的健康高级研究计划署（ Advanced Research Projects Agency for Health ， ARPA-H ）负责一个精准肿瘤学项目。 他对《财富》杂志表示："我们完全有可能在未来八年内，借助 AI 和大数据在抗击癌症方面取得巨大进 展。但单靠 AI 本身解决不了癌症问题。" 真正的瓶颈：数据，而非算力 尽管 Lux 和 Discovery 性能强大，但没有"燃料"也无法学习。艾德克认为，该领域最大的挑战在于整合 多模态数据 —— 从基因序列到组织切片，再到身体影像 —— 这些数据对于预测患者对治疗的反应至关 重要。 他将癌症研究的数据短缺与其他 AI 领域进行了对比。像 ChatGPT 这样的大语言模型（ LLM ）拥有互 联网数据；像 Waymo 这样的自动驾驶汽车拥有数百万小时的道路行驶记录。相比之下，癌症研究只能 获取医院能够且愿意共享的数据 美国政府正投入 10 亿美元，押 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 为什么有些人年近七旬仍精神矍铄，而有些人才三十出头却已显老态？ " 实际年龄 " （ Chronological Age，CA ） 显然无法完全解释这种差异。相对于 实际年龄 ，" 生物学年龄 " （Biological Age，BA） 能够更准确地评估一个人的实际衰老 程度， 目前，主要通过 衰老时钟 （ | Aging Clock ） | | 来评估一个人的生物学 | | --- | --- | --- | | 年龄，然而，这些研究通常是在成年人中进行的，这导致了我们在 | | 理解贯穿整个生命周期的 | | 生物学时钟方面仍留有关键空白，尤其是在 | 婴儿期 | 和 儿童期 | 。 作，在国际顶尖医学期刊 Nature Medicine 上发表了题为： A 2025 年 10 月 27 日，温州医科大学/澳门科技大学 张康 教 授团队与 解放军总医院第一医学中心 陈香美 院士团队合 full life cycle biological clock based on routine clinical data and its impact in health and ...

Core Insights - Lanzhou Foci Pharmaceutical Co., Ltd. reported a strong performance in Q3 2025, with a revenue of 1.95 billion yuan and a net profit of 797.78 million yuan, marking a year-on-year growth of 167.92% [1] - The company achieved a net cash flow from operating activities of 935.05 million yuan, indicating a positive turnaround and providing solid financial support for future operations and innovations [1] Group 1: Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 6.24 billion yuan and a net profit attributable to shareholders of 380.82 million yuan [1] - The Q3 performance was particularly notable, with a revenue of 1.95 billion yuan and a net profit of 797.78 million yuan, reflecting a significant increase of 167.92% year-on-year [1] Group 2: Market Strategy - The company has been optimizing its marketing structure and market layout, enhancing channel development and management to increase product market share [2] - Foci Pharmaceutical maintains a balanced sales network, with over 60% of sales from commercial chains and approximately 20% from medical and online channels [2] - The company has successfully expanded its market coverage to regions such as South China, East China, North China, Southwest China, and overseas markets [2] Group 3: International Expansion - Foci Pharmaceutical has exported products to 32 countries and regions, with 1,442 product registrations abroad, maintaining a leading position in international certifications and trademark registrations [2] - The company has received various international GMP certifications, including from Australia and Japan, establishing a strong quality barrier [2] Group 4: Strategic Investments - In October 2023, Foci Pharmaceutical announced a cash investment of 20 million yuan to acquire a 4.91% stake in Kexin Technology Co., Ltd., marking its entry into the promising field of radioactive isotope drugs [3] - This strategic investment aligns with the company's shift from traditional Chinese medicine to precision medicine, resonating with national policies aimed at developing high-end pharmaceutical industries [3]

Core Viewpoint - 华大智造's stock has experienced fluctuations, with a year-to-date increase of 37.23% but a recent decline in the last five trading days by 6.66% [1] Company Overview - Shenzhen Huada Zhizao Technology Co., Ltd. was established on April 13, 2016, and listed on September 9, 2022. The company focuses on the life sciences and biotechnology sectors, specializing in the research, production, and sales of instruments, equipment, and consumables [2] - The main revenue composition includes 90.89% from sales of instruments and consumables, 7.10% from services, and 2.01% from other sources [2] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and equipment, with concepts including gene sequencing, synthetic biology, medical devices, and precision medicine [2] Financial Performance - For the period from January to September 2025, Huada Zhizao reported operating revenue of 1.869 billion yuan, a slight decrease of 0.01% year-on-year, while the net profit attributable to shareholders was -120 million yuan, reflecting a significant increase of 74.20% year-on-year [2] - Cumulatively, the company has distributed 150 million yuan in dividends since its A-share listing [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 14.17% to 15,400, with an average of 26,794 circulating shares per person, up by 69.94% [2] - The top ten circulating shareholders include various ETFs, with notable reductions in holdings for several funds [3]

Core Viewpoint - Eli Lilly collaborates with NVIDIA to build a powerful supercomputer and AI factory aimed at accelerating drug development in the pharmaceutical industry, expected to launch in January next year [2][4]. Group 1: AI in Drug Development - The pharmaceutical industry's efforts to utilize AI for accelerating drug approvals are still in the early stages, with no AI-designed drugs yet on the market, but an increase in AI-discovered drugs entering clinical trials [4]. - Eli Lilly's Chief AI Officer, Thomas Fuchs, describes the supercomputer as a novel scientific instrument, akin to a giant microscope for biologists [5]. - The supercomputer will enable scientists to train AI models through millions of experiments, significantly expanding the scope and complexity of drug discovery [6]. Group 2: Precision Medicine - The new AI tools are not solely focused on drug discovery but represent a significant opportunity to discover new molecules that humans may not identify [7]. - Eli Lilly emphasizes that new scientific AI agents can support researchers and advanced medical imaging can help in observing disease progression and developing biomarkers for precision treatment [9][10]. - NVIDIA's healthcare VP, Kimberly Powell, states that achieving the promise of precision medicine requires AI infrastructure, which is being built, with Eli Lilly serving as a prime example [11]. Group 3: Open Platform for Data Sharing - Multiple AI models will be available on the Lilly TuneLab platform, launched by Eli Lilly in September last year, which allows biotech companies to access drug discovery models trained on proprietary research data valued at $1 billion [13]. - The platform aims to broaden industry access to drug discovery tools, with Powell noting the significance of assisting startups that might otherwise take years to reach similar stages [14]. - In exchange for access to the platform, biotech companies are expected to contribute some of their research and data to help train the AI models [15].

Core Viewpoint - Eli Lilly collaborates with NVIDIA to build a powerful supercomputer and AI factory aimed at accelerating drug development, expected to launch in January next year [1][3] Group 1: Supercomputer and AI Factory - The supercomputer will consist of over 1,000 NVIDIA Blackwell Ultra GPUs connected through a unified high-speed network [3] - The system is designed to power an AI factory specifically for large-scale development, training, and deployment of AI models in drug discovery [3] - Eli Lilly's Chief Information and Digital Officer, Diogo Rau, indicated that significant returns from these new tools may not be realized until 2030 [3][6] Group 2: AI in Drug Discovery - Currently, no drugs designed using AI have been approved, but there is an increase in the number of AI-discovered drugs entering clinical trials [5] - Eli Lilly's Chief AI Officer, Thomas Fuchs, described the supercomputer as a novel scientific instrument that will allow scientists to train AI models through millions of experiments [6] - Rau emphasized that while drug discovery is a major focus, the new tools will also support other research areas [7] Group 3: Precision Medicine - Eli Lilly plans to use the supercomputer to shorten drug development cycles and enhance treatment efficacy [8] - Precision medicine aims to customize disease prevention and treatment based on individual genetic, environmental, and lifestyle differences [9] - NVIDIA's healthcare VP, Kimberly Powell, stated that AI infrastructure is essential for realizing the promise of precision medicine [10] Group 4: Data Sharing and Collaboration - Multiple AI models will be available on the Lilly TuneLab platform, which was launched last September, allowing biotech companies access to Eli Lilly's drug discovery models valued at $1 billion [12] - The platform aims to broaden industry access to drug discovery tools, with biotech companies contributing their research and data to help train AI models [13]

Financial Data and Key Metrics Changes - The company reported third quarter 2025 revenues of $116.7 million, a 52% increase year-over-year [14] - Adjusted gross margin expanded to 74%, driven by favorable mix shift, improved reimbursement, and lower COGS [17] - Adjusted net income for the quarter was $14.7 million, with adjusted basic EPS of $0.51 [21] Business Line Data and Key Metrics Changes - Revenue from exome and genome testing was $98.9 million, up 66% from the same quarter last year [14] - The company conducted 25,702 exome and genome tests in the third quarter, with growth accelerating from 24% year-over-year in Q1 to 33% in Q3 [14] - The hereditary cancer offerings were discontinued, generating $1.2 million in Q3 2025, down from $3.3 million in the same quarter last year [22] Market Data and Key Metrics Changes - The average reimbursement rate for exome and genome testing was over $3,800 in Q3, up from approximately $3,700 in the previous quarter [16] - The NICU market remains underpenetrated, with less than 5% of NICU patients receiving genetic testing [10] - The company is on track to activate at least 12 Epic Aura integrations by the end of the year [10] Company Strategy and Development Direction - The company aims to drive high profitable growth, offer best-in-class diagnostics, and build a network for precision medicine [6] - GeneDx Infinity, the largest rare disease dataset, is leveraged to generate genomic insights and enable fast diagnoses [7] - The company plans to nearly double its sales force over the coming quarters to enhance market penetration [9] Management's Comments on Operating Environment and Future Outlook - Management raised 2025 revenue guidance to $425 million-$428 million, reflecting strong momentum [5] - The company is focused on transforming healthcare from reactive to proactive, particularly in newborn screening [11] - Management expressed confidence in maintaining profitability while investing in long-term growth [19] Other Important Information - The FDA granted breakthrough device designation to ExomeDx and GenomeDx tests, validating the company's technology [7] - The company is expanding its international market presence and has begun hiring for key positions [12][8] - The company generated $9 million in free cash flow during the third quarter [21] Q&A Session Summary Question: Has there been an uptick in volume due to the AAP guidelines? - Management noted that most pediatricians are hearing about the guidelines from GeneDx and emphasized the need for education [31] Question: What is the outlook for average selling prices and margins? - Management indicated that ASPs may decrease slightly due to new market entries but remains optimistic about long-term margins [34][37] Question: What is the status of the NICU market? - Management confirmed that NICU volumes are growing and that they are on track to activate more systems [40][44] Question: Can you elaborate on OpEx spending and its impact? - Management stated that OpEx is expected to increase as they build out the sales team and invest in growth initiatives [47][49] Question: What is the plan for the sales force expansion? - Management plans to double the sales force and is currently hiring Regional Sales Directors to lead the effort [52][53] Question: What is the expected impact of the FDA breakthrough designation? - Management believes the designation will enhance market access and validate their technology among clinicians [63][68]